Mankind Pharma reported a 21 percent year-on-year decline in consolidated net profit for the quarter ended September 30, 2025, with profit falling to approximately INR 520 crore from INR 661 crore in the same period last year.

Despite the drop in profit, the company’s revenue from operations rose by around 20.8 percent to about INR 3,697 crore, compared to INR 3,061 crore in the corresponding quarter of the previous year.

The decline in profit was largely attributed to weaker sales in its over-the-counter (OTC) segment, as supply chain disruptions and changes in goods and services tax (GST) regulations reportedly delayed distributor purchases.

While challenges remain in the OTC business, Mankind Pharma noted that its chronic therapies and vaccine segments continued to perform well. The company expressed confidence in its long-term growth outlook, focusing on expanding its chronic care, specialty, and high-potential OTC portfolios to strengthen its market position.